Skip to main content

Month: September 2025

MACOM to Highlight Cutting-Edge RF, Microwave and mmWave Solutions at European Microwave Week 2025

LOWELL, Mass., Sept. 18, 2025 (GLOBE NEWSWIRE) — MACOM Technology Solutions Inc. (“MACOM”), a leading supplier of semiconductor products, invites attendees of European Microwave Week (EuMW) 2025 in Utrecht, Netherlands to visit Booth #D068 from September 23 to 25, 2025 and review its broad portfolio of RF, microwave and millimeter wave (mmWave) product solutions, and foundry services. MACOM will exhibit a variety of demonstrations that highlight its expanding product capabilities for space, radar, RF-over-Fiber (RFoF) and high reliability applications. Attendees will have the opportunity to engage with MACOM’s technical experts and explore how its technologies support next-generation performance across commercial and aerospace markets. EuMW 2025 demonstrations will include: SATCOM Applications:Ka-Band Power Amplifier (PA) and...

Continue reading

Health Canada Grants Quantum BioPharma a Product License for Its Innovative Product, Qlarity™, that Enhances Energy, and Promotes Metabolism, Mental Alertness and Cognitive Performance

TORONTO, Sept. 18, 2025 (GLOBE NEWSWIRE) — Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (Upstream: QNTM) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development, announces that Health Canada has granted a Product License (PN 80144141) for its natural health product, Qlarity. Quantum licensed a similar product, as a dietary supplement, for sale in the United States under the brand name unbuzzd™ (unbuzzd.com). This Product License from Health Canada permits Quantum to sell Qlarity in Canada. Health Canada’s product license permits the following recommended uses...

Continue reading

NKGen Biotech to Present on the Use of Troculeucel for Neurodegenerative Diseases at the 3rd China Great Bay Cell and Gene Therapy Forum

SANTA ANA, Calif., Sept. 18, 2025 (GLOBE NEWSWIRE) — NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer (“NK”) cell therapeutics, today announced that Paul Y. Song, M.D., Chairman and Chief Executive Officer of NKGen, will present at the 3rd China Great Bay Cell and Gene Therapy Forum, taking place in Guangzhou, China, September 25-26, 2025. Dr. Song will discuss the scientific rationale and recent clinical data supporting the use of the investigational autologous enhanced NK cell therapy, troculeucel, in the treatment of neurodegenerative diseases. This presentation underscores NKGen’s commitment to advancing innovative NK cell-based approaches in the rapidly evolving cell and...

Continue reading

Nanox Announces Multi-Segment Healthcare Collaboration with Monarch Medical Management to Expand Access to Advanced Medical Imaging

Collaboration spans workers’ compensation, nursing homes, and outpatient clinics PETACH TIKVA, Israel, Sept. 18, 2025 (GLOBE NEWSWIRE) — NANO-X IMAGING LTD (“Nanox” or the “Company”, Nasdaq: NNOX), an innovative medical imaging technology company, today announced a collaboration between its U.S. subsidiary Nanox Impact Inc. and Monarch Medical Management and Billing LLC (“Monarch”), an experienced healthcare management organization with established relationships across industry sectors, to deploy Nanox’s advanced imaging solutions across multiple healthcare segments including workers’ compensation, nursing home facilities, and outpatient clinics. As part of the collaboration, Nanox will establish a comprehensive imaging network by deploying its technology across Monarch’s associated...

Continue reading

DIRTT to Present at Two Upcoming Investor Conferences – Smallcap Discoveries Conference, Vancouver and Planet MicroCap Showcase, Toronto

CALGARY, Alberta, Sept. 18, 2025 (GLOBE NEWSWIRE) — DIRTT Environmental Solutions Ltd. (“DIRTT”, the “Company”, “we”, “our”, “us” or “ours”) (TSX: DRT; OTCQX: DRTTF), a leader in industrialized construction, today announced it will be participating at two upcoming investor conferences: the Smallcap Discoveries Conference in Vancouver and the Planet MicroCap Showcase in Toronto. Smallcap Discoveries Conference, VancouverDate: Monday, September 29, 2025DIRTT Environmental Solutions Presentation: 1:15 pm PTVenue: JW Marriott Parq, VancouverClick here to register: REGISTER Planet MicroCap Showcase, TorontoDate: Wednesday, October 22, 2025DIRTT Environmental Solutions Presentation: 3:00 pm ETVenue: Arcadian Court & Loft, TorontoClick here to register: REGISTER About DIRTT Environmental Solutions Ltd.DIRTT is a leader in industrialized...

Continue reading

Tonix Pharmaceuticals Announces Positive Pre-IND Meeting with FDA for TNX-102 SL for the Treatment of Major Depressive Disorder

Tonix anticipates filing the IND application in the fourth quarter of 2025 TNX-102 SL is a potential first-in-class treatment for targeting the disturbed sleep associated with depression TNX-102 SL is FDA-approved for the treatment of fibromyalgia CHATHAM, N.J., Sept. 18, 2025 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a fully-integrated biotechnology company with marketed products and a pipeline of development candidates, today announced the successful completion of a Type B Pre-Investigational New Drug (Pre-IND) meeting with the U.S. Food and Drug Administration (FDA) regarding the development of TNX-102 SL (sublingual cyclobenzaprine HCl) for the treatment of major depressive disorder (MDD). The Company received positive feedback from the FDA and plans to pursue a supplemental new drug application...

Continue reading

ZenaTech Signs Offer to Acquire Washington Land Surveying and Mapping Firm Expanding Drone as a Service (DaaS) in the Northwest Tapping into an $8.5 Billion US Market

VANCOUVER, British Columbia, Sept. 18, 2025 (GLOBE NEWSWIRE) — ZenaTech, Inc. (Nasdaq: ZENA) (FSE: 49Q) (BMV: ZENA) (“ZenaTech”), a business technology solution provider specializing in AI (Artificial Intelligence) drones, Drone as a Service (DaaS), Enterprise SaaS, and Quantum Computing solutions, today announces that it has signed an offer to acquire a well-established land surveying and mapping firm located in the state of Washington with a history of customers and past project success spanning across both Washington and Idaho. “When closed, we anticipate this acquisition will give us another location in our rapidly expanding US Drone as a Service business, establishing a strong foothold in the Northwest and unlocking significant opportunity particularly in drone-based land and marine surveys,” said Shaun Passley,...

Continue reading

Aveanna Healthcare Announces Successful Debt Refinancing

ATLANTA, Sept. 18, 2025 (GLOBE NEWSWIRE) — Aveanna Healthcare Holdings Inc. (“Aveanna”) (Nasdaq: AVAH) today announced the closing of its refinanced first lien credit facility. The refinanced credit facility provides for the refinancing of the $886.0 million principal balance of existing first lien term loans, the additional borrowing of $439.0 million in incremental first lien term loans, and the upsize of its revolving credit facility from $170.3 million of maximum availability to $250.0 million of maximum availability. The combined $1.325 billion first lien term loans’ maturity dates were extended to 2032, and the revolving credit facility’s maturity date was extended from 2028 to 2030. Proceeds from the incremental first lien term loans were used to repay in full the existing second lien term loans in the amount of $415.0...

Continue reading

Statkraft aim to produce more electricity at the Alta hydropower plant

(Alta, Norway 18 September 2025) Statkraft has submitted a license application for an upgrade of the Alta power plant. By utilizing water currently bypassing the plant during floods, production could increase by up to 20 percent. This will be achieved by installing a third turbine, with minimal new environmental impact. The water flow in the salmon-carrying stretch of the Alta River will not be changed. When the Alta power plant was built in the 1980s, the facility was designed to accommodate three turbines. Due to grid limitations in Finnmark at the time, only two were installed. The turbine is a part of the installation that generates electricity from the energy in the water. Since the power grid has been reinforced in recent years, it can now handle more electricity. Statkraft is therefore applying for a license to increase power generation...

Continue reading

Plus Therapeutics Announces Successful Accreditation and Certification for Its CNSide® Diagnostics Clinical Laboratory

Certification critical to broad U.S. market release of the CNSide CSF Assay Platform CNSide now meets key federal and state regulatory requirements, including those set by the Centers for Medicare and Medicaid Services (CMS) under the Clinical Lab Improvement Amendments (CLIA) HOUSTON, Texas, Sept. 18, 2025 (GLOBE NEWSWIRE) — CNSide Diagnostics, LLC, a wholly-owned subsidiary of Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, announces that it has received a certificate of accreditation from CMS for its lab located in Houston, Texas. Following the recent planned laboratory audit, successful certificate of accreditation deems the lab compliant with Clinical...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.